<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03547141</url>
  </required_header>
  <id_info>
    <org_study_id>MT14-KR18EDB102</org_study_id>
    <nct_id>NCT03547141</nct_id>
  </id_info>
  <brief_title>Pharmacodynamic and Safety of MBA-P01 in Healthy Male Volunteers</brief_title>
  <official_title>A Randomized, Double-blind, Active-controlled, Single-center, Phase 1 Study to Determine the Pharmacodynamic and Safety of MBA-P01 in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medy-Tox</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medy-Tox</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the pharmacodynamic and safety of MBA-P01 in Healthy Male Volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 16, 2018</start_date>
  <completion_date type="Actual">November 1, 2018</completion_date>
  <primary_completion_date type="Actual">August 28, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>to estimate the pharmacodynamic aspects of muscle</measure>
    <time_frame>day 3, 14, week 4, 8, 12</time_frame>
    <description>percentage of reduction of CMAP amplitude of the muscle from baseline</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>botulinum toxin 1U</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>botulinum toxin 5U</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>botulinum toxin 15U</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>botulinum toxin 30U</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MBA-P01</intervention_name>
    <description>injection of MBA-P01 into the muscle of each contralateral foot in equal doses</description>
    <arm_group_label>botulinum toxin 15U</arm_group_label>
    <arm_group_label>botulinum toxin 1U</arm_group_label>
    <arm_group_label>botulinum toxin 30U</arm_group_label>
    <arm_group_label>botulinum toxin 5U</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BOTOX</intervention_name>
    <description>injection of BOTOX into the muscle of each contralateral foot in equal doses</description>
    <arm_group_label>botulinum toxin 15U</arm_group_label>
    <arm_group_label>botulinum toxin 1U</arm_group_label>
    <arm_group_label>botulinum toxin 30U</arm_group_label>
    <arm_group_label>botulinum toxin 5U</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male adults aged between 20 and 45 years

        Exclusion Criteria:

          -  Subjects not appropriate for participating in this study according to the
             investigator's opinion
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myungeun Chung</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic University, St. Paul's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Catholic University of Korea, St. Paul's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>April 29, 2018</study_first_submitted>
  <study_first_submitted_qc>May 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2018</study_first_posted>
  <last_update_submitted>March 25, 2019</last_update_submitted>
  <last_update_submitted_qc>March 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

